28 not yet recruiting, 25 recruiting, 12 completed, 6 terminated. 24 Phase 1, 22 Phase 2, 13 Not applicable, 7 Phase 3, 6 Early Phase 1.
Follow Multiple Myeloma (MM): new trials by email Literature Review of Multiple Myeloma (MM) trials Research Report on Multiple Myeloma (MM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma CM336, CM313, Daratumumab - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 320 | 2026-12-01 | 2026-11-02 |
| QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease QLS4131 - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 55 | 2026-12-01 | 2026-10-29 |
| Neurocognitive Trajectories After BCMA CAR-T Standardized neurocognitive testing - Multiple Myeloma (MM), CART Therapy | Recruiting | Wake Forest University Health Sciences | 50 | 2026-11-01 | 2026-10-23 | |
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Not yet recruiting | Umoja Biopharma | 100 | 2026-10-01 | 2026-08-17 |
| F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-09-18 |
| Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" DW-MRI (MY-RADS/RAC score), Fat Fraction (rFF%), Clinical Data Collection - Multiple Myeloma (MM) | Not yet recruiting | Fondazione EMN Italy Onlus | 92 | 2026-10-01 | 2026-09-09 | |
| Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma anti-BCMA/CD3 bispecific antibody - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2026-10-01 | 2026-08-27 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment CM336 Plus Isatuximab - Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 26 | 2026-09-10 | 2026-09-17 |
| HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease HP-001, Dexamethasone - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-09-01 | 2026-09-10 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Sonrotoclax, CM336 (BCMA/CD3 bispecific antibody) - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-08-01 | 2026-07-07 |
| Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention Gustabor server, Standard Recommendations - Multiple Myeloma (MM), GI Cancer | Not applicable | Recruiting | Wuerzburg University Hospital | 198 | 2026-07-24 | 2026-08-20 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma RN9101 injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 19 | 2026-07-01 | 2026-06-10 |
| PET-Enabled Dual-Energy CT in Multiple Myeloma PET-enabled dual-energy CT imaging, X-ray dual-energy CT imaging - Multiple Myeloma (MM) | Not applicable | Not yet recruiting | University of California, Davis | 45 | 2026-07-01 | 2026-06-15 |
| GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders GPRC5D-Targeted PET/CT Imaging - Plasma Cell Disorders, Multiple Myeloma (MM) | Phase 1 | Recruiting | Peking University First Hospital | 50 | 2026-06-25 | 2026-09-28 |
Showing 20 of 75. Sign in to see all of them.
Multiple Myeloma (75) · Leukemia, Myeloid, Acute (7) · Recurrence (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Neoplasms (4) · Hematologic Neoplasms (3) · Leukemia, B-Cell (3) · Lymphoma (3) · Myelodysplastic Syndromes (3) · Smoldering Multiple Myeloma (3) · Burkitt Lymphoma (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Plasma Cell (2) · Lymphoma, B-Cell (2)
Blood Protein Disorders (75) · Cardiovascular Diseases (75) · Hematologic Diseases (75) · Hemic and Lymphatic Diseases (75) · Hemorrhagic Disorders (75) · Hemostatic Disorders (75) · Immune System Diseases (75) · Immunoproliferative Disorders (75) · Neoplasms by Histologic Type (75) · Paraproteinemias (75) · Vascular Diseases (75) · Lymphoproliferative Disorders (74) · Neoplasms, Plasma Cell (74) · Neoplasms (71) · Pathological Conditions, Signs and Symptoms (18)
Lenalidomide (9) · Dexamethasone (8) · daratumumab (8) · Bortezomib (4) · talquetamab (4) · Cyclophosphamide (3) · Melphalan (2) · fludarabine (2) · isatuximab (2) · Antibodies, Bispecific (1) · Antibodies, Monoclonal (1) · Blood Specimen Collection (1) · Calcium Dobesilate (1) · Ceftazidime (1) · Ciprofloxacin (1)
Institute of Hematology & Blood Diseases Hospital, China (8) · AbbVie (3) · Azienda USL Reggio Emilia - IRCCS (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Gilead Sciences (2) · Keymed Biosciences Co.Ltd (2) · Novartis Pharmaceuticals (2) · SCRI Development Innovations, LLC (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Acerta Pharma BV (1) · Alliance for Clinical Trials in Oncology (1) · Anhui Provincial Hospital (1) · Benovus Bio, Inc. (1) · Biotroy Therapeutics (1) · C4 Therapeutics, Inc. (1)
China (21) · United States (20) · Italy (10) · Spain (7) · Germany (6) · Australia (5) · France (5) · Japan (5) · Israel (4) · Norway (3) · South Korea (3) · United Kingdom (3) · Belgium (2) · Canada (2) · Netherlands (2)
Lugui Qiu (2) · Alessandra Larocca (1) · Antonino Neri, MD, PhD (1) · Antonio Palumbo, MD (1) · Charlotte Pawlyn (1) · Cindy Varga, MD (1) · Daniel Couriel, M.D. (1) · David Ogez, Ph.D (1) · Elena Zamagni, MD, PhD (1) · Enrique Ocio San Miguel, MD, PhD (1) · Fredrik Schjesvold (1)
PMID 21816833, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24733536, PMID 25486127, PMID 27025228, PMID 29133316, PMID 30069704, PMID 31314918, PMID 32383192, PMID 34774221, PMID 34939484, PMID 35666982, PMID 36528035, PMID 36764323, PMID 37024520, PMID 37880389, PMID 38048557, PMID 38849344, PMID 40829119, PMID 41162921, PMID 41758815
2025 (3), 2018 (1), R01CA300310 (1), R01EB036562 (1)